Literature DB >> 11466178

Varicella vaccination--a critical review of the evidence.

S A Skull1, E E Wang.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11466178      PMCID： PMC1718891          DOI： 10.1136/adc.85.2.83

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  89 in total

1.  Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic.

Authors:  T Ozaki; N Nishimura; Y Kajita
Journal:  Vaccine       Date:  2000-05-08       Impact factor: 3.641

2.  Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother.

Authors:  M B Salzman; R G Sharrar; S Steinberg; P LaRussa
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

3.  A long-term prospective study of varicella vaccine in healthy children.

Authors:  C E Johnson; T Stancin; D Fattlar; L P Rome; M L Kumar
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

4.  Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates.

Authors:  E P Rothstein; H H Bernstein; A L Ngai; I Cho; C J White
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

5.  Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.

Authors:  C J White; D Stinson; B Staehle; I Cho; H Matthews; A Ngai; P Keller; J Eiden; B Kuter
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

6.  Community impact of childhood varicella infections.

Authors:  B P Yawn; R A Yawn; E Lydick
Journal:  J Pediatr       Date:  1997-05       Impact factor: 4.406

Review 7.  Immunology of Varicella Immunization in the elderly.

Authors:  C K Raeder; M S Hayney
Journal:  Ann Pharmacother       Date:  2000-02       Impact factor: 3.154

8.  Postmarketing evaluation of the safety and effectiveness of varicella vaccine.

Authors:  S Black; H Shinefield; P Ray; E Lewis; J Hansen; J Schwalbe; P Coplan; R Sharrar; H Guess
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

9.  Postlicensure study of varicella vaccine effectiveness in a day-care setting.

Authors:  D A Clements; S P Moreira; P M Coplan; C L Bland; E B Walter
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

10.  Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts.

Authors:  P LaRussa; S Steinberg; F Meurice; A Gershon
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226
View more
  8 in total

Review 1.  [Immunization: Leaps into the future. Foreseeable changes in children's vaccination calendar in the coming years].

Authors:  J Pericas Bosch
Journal:  Aten Primaria       Date:  2003-03-31       Impact factor: 1.137

2.  [Evidence-based treatment of skin diseases caused by herpesvirus].

Authors:  V Mahler
Journal:  Hautarzt       Date:  2005-03       Impact factor: 0.751

Review 3.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

4.  The impact of ten years of infant universal Varicella vaccination in Sicily, Italy (2003-2012).

Authors:  Emanuele Amodio; Fabio Tramuto; Manuela Cracchiolo; Valentina Sciuto; Antonella De Donno; Marcello Guido; Maria Cristina Rota; Giovanni Gabutti; Francesco Vitale
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 5.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 6.  Chickenpox.

Authors:  Judith Breuer; Helen Fifer
Journal:  BMJ Clin Evid       Date:  2011-04-11

7.  Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study.

Authors:  Saul N Faust; Maguelone Le Roy; Chitsanu Pancharoen; Miguel Angel Rodriguez Weber; Katrina Cathie; Ulrich Behre; Jolanta Bernatoniene; Matthew D Snape; Klaus Helm; Carlos Eduardo Medina Pech; Ouzama Henry; Carmen Baccarini; Michael Povey; Paul Gillard
Journal:  BMC Pediatr       Date:  2019-02-07       Impact factor: 2.125

8.  Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial.

Authors:  Roman Prymula; Robert Simko; Michael Povey; Andrea Kulcsar
Journal:  BMC Pediatr       Date:  2016-01-13       Impact factor: 2.125
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.